Massimo Filippi1, Paolo Preziosa, Maria A Rocca. 1. Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Abstract
PURPOSE OF REVIEW: We summarize MRI measures currently available to assess treatment efficacy and safety in multiple sclerosis (MS) clinical trials and discuss novel metrics that could enter the clinical arena in the near future. RECENT FINDINGS: In relapsing remitting MS, MRI measures of disease activity (new T2 and gadolinium-enhancing lesions) provide a good surrogacy of treatment effect on relapse rate and disability progression; however, their value in progressive MS remains elusive. For the progressive disease forms, these measures need to be combined with quantities assessing the extent of irreversible tissue loss, which have already been introduced in some clinical trials (e.g., evolution of active lesions into permanent black holes and brain atrophy). Novel measures (e.g., quantification of gray matter and spinal cord atrophy) have demonstrated a great value in explaining patients' clinical outcome, but still need to be fully validated. Despite showing promise, evaluations of cortical lesions, of microscopic tissue abnormalities, and of functional cortical reorganization are still some way off for monitoring of treatment effects. SUMMARY: Trial outcomes in MS should include measures of inflammation and neurodegeneration, which should be combined according to the disease clinical phenotype, phase of the study, and the supposed mechanism of action of the drug tested.
PURPOSE OF REVIEW: We summarize MRI measures currently available to assess treatment efficacy and safety in multiple sclerosis (MS) clinical trials and discuss novel metrics that could enter the clinical arena in the near future. RECENT FINDINGS: In relapsing remitting MS, MRI measures of disease activity (new T2 and gadolinium-enhancing lesions) provide a good surrogacy of treatment effect on relapse rate and disability progression; however, their value in progressive MS remains elusive. For the progressive disease forms, these measures need to be combined with quantities assessing the extent of irreversible tissue loss, which have already been introduced in some clinical trials (e.g., evolution of active lesions into permanent black holes and brain atrophy). Novel measures (e.g., quantification of gray matter and spinal cord atrophy) have demonstrated a great value in explaining patients' clinical outcome, but still need to be fully validated. Despite showing promise, evaluations of cortical lesions, of microscopic tissue abnormalities, and of functional cortical reorganization are still some way off for monitoring of treatment effects. SUMMARY: Trial outcomes in MS should include measures of inflammation and neurodegeneration, which should be combined according to the disease clinical phenotype, phase of the study, and the supposed mechanism of action of the drug tested.
Authors: Ileana O Jelescu; Magdalena Zurek; Kerryanne V Winters; Jelle Veraart; Anjali Rajaratnam; Nathanael S Kim; James S Babb; Timothy M Shepherd; Dmitry S Novikov; Sungheon G Kim; Els Fieremans Journal: Neuroimage Date: 2016-02-11 Impact factor: 6.556
Authors: Aaron Carass; Snehashis Roy; Amod Jog; Jennifer L Cuzzocreo; Elizabeth Magrath; Adrian Gherman; Julia Button; James Nguyen; Ferran Prados; Carole H Sudre; Manuel Jorge Cardoso; Niamh Cawley; Olga Ciccarelli; Claudia A M Wheeler-Kingshott; Sébastien Ourselin; Laurence Catanese; Hrishikesh Deshpande; Pierre Maurel; Olivier Commowick; Christian Barillot; Xavier Tomas-Fernandez; Simon K Warfield; Suthirth Vaidya; Abhijith Chunduru; Ramanathan Muthuganapathy; Ganapathy Krishnamurthi; Andrew Jesson; Tal Arbel; Oskar Maier; Heinz Handels; Leonardo O Iheme; Devrim Unay; Saurabh Jain; Diana M Sima; Dirk Smeets; Mohsen Ghafoorian; Bram Platel; Ariel Birenbaum; Hayit Greenspan; Pierre-Louis Bazin; Peter A Calabresi; Ciprian M Crainiceanu; Lotta M Ellingsen; Daniel S Reich; Jerry L Prince; Dzung L Pham Journal: Neuroimage Date: 2017-01-11 Impact factor: 6.556
Authors: Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli Journal: Nat Rev Neurol Date: 2018-01-12 Impact factor: 42.937
Authors: Michael O Breckwoldt; Johann Gradl; Stefan Hähnel; Thomas Hielscher; Brigitte Wildemann; Ricarda Diem; Michael Platten; Wolfgang Wick; Sabine Heiland; Martin Bendszus Journal: J Neurol Date: 2016-12-01 Impact factor: 4.849